Apraclonidine hydrochloride

Research use only, not for human use.

Apraclonidine hydrochloride (ALO 2145) is an α2-adrenergic agonist and a weak α-1 adrenergic receptor agonist.

Apraclonidine hydrochloride (ALO 2145), a selective α2 and weak α1 receptor agonist activity, effectively lowers intraocular pressure (IOP) in human eyes. Apraclonidine hydrochloride is a topical ophthalmic solution and has the ability to elevate the eye lid.

Apraclonidine hydrochloride (ALO 2145) is more commonly used topically for glaucoma, as it penetrates the cornea and blood-brain barrier to a lesser extent and, thus, has fewer adverse systemic effects.

Apraclonidine hydrochloride (ALO 2145) is effective in animal models of elevated IOP as well as glaucoma in humans. The ocular hypotensive effects of Apraclonidine are usually attributed to reduced aqueous humor synthesis and vasoconstrictor actions at the anterior segment branches of the ophthalmic artery.Apraclonidine (1.15%, single instillation) inhibits 98% of PGE2-induced aqueous flare elevationy.Animal Model:male rabbits.Dosage:1.15% Administration:Apraclonidine (1.15%, single instillation)Result:Inhibited PGE2-induced elevation of aqueous flare in pigmented rabbits.

——

GPCR/G Protein

Adrenergic Receptor

Adrenergic Receptor

——

——

73218-79-8

281.57

C9H11Cl3N4

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (443.94 mM; Ultrasonic )H2O : ≥ 12.5 mg/mL (44.39 mM)

Cl.Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1

——

(-20℃)

With Ice Pack

≥ 2 years